Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline Review, H2 2016

Published by Global Markets Direct on 14th December 2016 | Ref: 204789 | This Product Is In Stock

$2000 | Single User
$4000 | Site License
$6000 | Enterprise License
$2000 | Single User
$4000 | Site License
$6000 | Enterprise License

Introduction

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peripheral Nerve Sheath Tumor – Pipeline Review, H2 2016, provides an overview of the Peripheral Nerve Sheath Tumor (Oncology) pipeline landscape.

Malignant peripheral nerve sheath tumors (MPNSTs) are sarcomas which originate from peripheral nerves or from cells associated with the nerve sheath, such as Schwann cells, perineural cells, or fibroblasts. Symptoms include lump or swelling in the in the soft tissue, numbness, burning or having that pins and needles feeling, weakness in the affected muscles and dizziness or loss of balance. Treatment includes surgery, radiotherapy and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peripheral Nerve Sheath Tumor – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Peripheral Nerve Sheath Tumor (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Peripheral Nerve Sheath Tumor (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Phase I stages are 5 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.Peripheral Nerve Sheath Tumor.

Peripheral Nerve Sheath Tumor (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Peripheral Nerve Sheath Tumor (Oncology).

- The pipeline guide reviews pipeline therapeutics for Peripheral Nerve Sheath Tumor (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Peripheral Nerve Sheath Tumor (Oncology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Peripheral Nerve Sheath Tumor (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Peripheral Nerve Sheath Tumor (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Peripheral Nerve Sheath Tumor (Oncology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Peripheral Nerve Sheath Tumor (Oncology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Overview 6

Therapeutics Development 7

Pipeline Products for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Overview 7

Pipeline Products for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Comparative Analysis 8

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Therapeutics under Development by Companies 9

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Therapeutics under Investigation by Universities/Institutes 10

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline Products Glance 11

Clinical Stage Products 11

Early Stage Products 12

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Products under Development by Companies 13

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Products under Investigation by Universities/Institutes 14

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Companies Involved in Therapeutics Development 15

Bexion Pharmaceuticals LLC 15

EpiZyme Inc 16

Merck & Co Inc 17

Novartis AG 18

Pfizer Inc 19

Plexxikon Inc 20

Vyriad Inc 21

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Therapeutics Assessment 22

Assessment by Monotherapy Products 22

Assessment by Target 23

Assessment by Mechanism of Action 25

Assessment by Route of Administration 27

Assessment by Molecule Type 29

Drug Profiles 31

axitinib - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

BXQ-350 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

everolimus - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

ganetespib - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

Oncolytic Virus to Target CD46 for Oncology - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

pembrolizumab - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

pexidartinib - Drug Profile 97

Product Description 97

Mechanism Of Action 97

R&D Progress 97

Small Molecules to Inhibit BRD4 for Malignant Peripheral Nerve Sheath Tumors - Drug Profile 101

Product Description 101

Mechanism Of Action 101

R&D Progress 101

tazemetostat - Drug Profile 102

Product Description 102

Mechanism Of Action 102

R&D Progress 102

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Dormant Projects 109

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Product Development Milestones 110

Featured News & Press Releases 110

Dec 26, 2013: UTSW study identifies potential therapeutic target for incurable, rare type of soft-tissue cancer 110

Appendix 111

Methodology 111

Coverage 111

Secondary Research 111

Primary Research 111

Expert Panel Validation 111

Contact Us 111

Disclaimer 112

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

204789 | GMDHC8800IDB

Number of Pages

112

Report Format

PDF

Related Reports

Title
Date Published
Price From
Link

Published by Global Markets Direct
31-03-2017

$2,000 USD

Published by Timetric
03-03-2017

$75 USD

Published by Global Markets Direct
28-02-2017

$2,000 USD

Published by The Business Research Company
05-12-2016

$1,000 USD

This report is published by Global Markets Direct

Global Markets Direct is a global market intelligence services company providing information research and analysis products and services.

Their highly qualified team of Researchers, Analysts and Solution Consultants use proprietary data sources and various tools and techniques to gather, analyse and represent the latest and the most reliable information essential for businesses to sustain a competitive edge.

Download Free Report Summary PDF

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline Review, H2 2016 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.